Telomir reveals promising preclinical data for Telomir-Zn

Telomir Pharmaceuticals, Inc. ( (TELO) ) has provided an update.

On February 17, 2026, Telomir Pharmaceuticals reported new preclinical in vitro data showing that its investigational compound Telomir-Zn reduced viable tumor cell counts across multiple human triple-negative breast cancer models representing distinct molecular subtypes. Near-complete tumor cell mortality was seen in MDA-MB-468 cells after 72 hours, while significant partial reductions were observed in HCC70 and MDA-MB-231 lines over the same period.

Supplemental iron was found to attenuate Telomir-Zn–induced tumor cell mortality, which the company said supports an iron-dependent mechanism consistent with previously reported intracellular metal-modulating activity. Telomir also cited earlier zebrafish xenograft work showing reduced tumor growth and metastasis in select TNBC models and noted it is expanding subtype evaluations, preparing a TNBC mouse xenograft study, and continuing IND-enabling work after GLP safety studies in rats and dogs showed no treatment-related toxicity.

The most recent analyst rating on (TELO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.

More about Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is a drug development company focused on investigational oncology therapies, including its metal-modulating compound Telomir-1 (Telomir-Zn). The company is advancing Telomir-Zn through preclinical safety and toxicology studies in preparation for clinical development targeting difficult-to-treat cancers such as triple-negative breast cancer (TNBC).

Average Trading Volume: 304,818

Technical Sentiment Signal: Sell

Current Market Cap: $37.48M

For a thorough assessment of TELO stock, go to TipRanks’ Stock Analysis page.